Assessment of quality of life (QoL) in breast cancer patients by using EORTC QLQ-C30 and BR-23 questionnaires: A tertiary care center survey in the western region of Saudi Arabia.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
    • Abstract:
      This cross-sectional study is aimed at assessing the quality of life in a cohort of breast cancer patients at the Oncology Department, King Abdulaziz University Hospital (KAUH), King Abdulaziz University (KAU), Jeddah, Saudi Arabia (SA), and to differentiate QoL among different groups. Mean time since diagnosis was 3.97±1.90 years. European Organization for Research and Treatment of Cancer Quality of Life Questionnaires-Core30 and BR23 (EORTC QLQ-C30 & BR23) were used to assess QoL in breast cancer survivors. ANOVA and independent t-test (parametric tests) were used for the categorical variables and Kruskal-Wallis and Mann-Whitney tests used for non-parametric tests. Linear regression analysis was done to measure predictors' significance and to calculate the coefficient of determination. Two hundred and eighty-four patients completed the survey. Global health status and functional scales, in most of the domains, were high, while symptom scales were moderate-to-low for most items, showing better QoL. Insomnia and fatigue were the most disturbing symptoms. Patients exhibited higher scores for body image and future perspective, while the least score is for sexual functioning. Global health, physical functioning, and role functioning were better in the age group ≤50 years (p<0.05). Premenopausal and perimenopausal patients showed a better level of functioning as compared to postmenopausal patients (p = 0.001). Premenopausal patients scored higher for sexual enjoyment, as compared to peri- and post-menopausal patients (p = 0.04). Systemic therapy side effects were more evident in the breast conservative surgery group. Predictors explained 8% of the variation in Physical functioning (R-squared = 0.08). A predictor that had a remarkable influence on physical functioning, as compared to the other predictors in the model, was menopausal status (P = 0.02). So, it was concluded that the breast cancer patients visiting our institute had a better quality of life regarding overall global health status as well as functional and symptom scales. Some issues, for instance, fatigue, insomnia, hair loss, and others, warrant good supportive therapy.
      Competing Interests: The authors have declared that no competing interests exist.
    • References:
      J Cancer Res Clin Oncol. 2008 Dec;134(12):1311-8. (PMID: 18504613)
      Breast. 2015 Jun;24(3):224-9. (PMID: 25704982)
      Gynecol Oncol. 2012 Mar;124(3):437-43. (PMID: 22138013)
      Saudi Med J. 2015 Oct;36(10):1176-80. (PMID: 26446327)
      J Clin Oncol. 1996 Oct;14(10):2756-68. (PMID: 8874337)
      Qual Life Res. 2013 Dec;22(10):2685-91. (PMID: 23532341)
      Asian Pac J Cancer Prev. 2016;17(4):1677-84. (PMID: 27221837)
      J Pain Symptom Manage. 2015 Apr;49(4):707-15. (PMID: 25461671)
      CA Cancer J Clin. 2014 Jan-Feb;64(1):52-62. (PMID: 24114568)
      Breast Cancer Res Treat. 2011 Aug;129(1):125-34. (PMID: 21340477)
      Ann Saudi Med. 2010 Sep-Oct;30(5):390-6. (PMID: 20697165)
      Ann Surg. 2015 Jun;261(6):1198-206. (PMID: 25654742)
      Palliat Support Care. 2016 Dec;14(6):621-627. (PMID: 27323905)
      BMC Cancer. 2013 Apr 28;13:212. (PMID: 23622020)
      Psychooncology. 2008 Apr;17(4):317-28. (PMID: 17721909)
      Lancet Oncol. 2013 Sep;14(10):e417-24. (PMID: 23993386)
      Health Qual Life Outcomes. 2015 Dec 30;13:205. (PMID: 26715073)
      Eur J Surg Oncol. 2015 Mar;41(3):426-32. (PMID: 25578249)
      Int J Surg. 2010;8(6):448-52. (PMID: 20601253)
      Rev Esc Enferm USP. 2014 Apr;48(2):357-67. (PMID: 24918897)
      Breast Cancer (Dove Med Press). 2017 Feb 09;9:51-58. (PMID: 28223845)
      J Sex Med. 2013 Feb;10 Suppl 1:16-20. (PMID: 23387908)
      Rev Bras Ginecol Obstet. 2015 Mar;37(3):119-26. (PMID: 25830645)
      Public Health. 2016 Jul;136:117-25. (PMID: 27085319)
      Gulf J Oncolog. 2012 Jan;(11):45-9. (PMID: 22227545)
      PLoS One. 2018 Jul 19;13(7):e0200966. (PMID: 30024978)
      J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. (PMID: 8433390)
      J Natl Cancer Inst. 2012 Mar 7;104(5):386-405. (PMID: 22271773)
      Am J Surg. 2013 Nov;206(5):625-31. (PMID: 24016705)
      CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. (PMID: 21296855)
      J Family Med Prim Care. 2017 Oct-Dec;6(4):824-831. (PMID: 29564271)
      Ann Oncol. 2007 Jan;18(1):173-82. (PMID: 17030550)
      Clin Breast Cancer. 2012 Apr;12(2):119-26. (PMID: 22444718)
      Support Care Cancer. 2014 Sep;22(9):2489-95. (PMID: 24728586)
      Health Psychol. 2016 Dec;35(12):1320-1328. (PMID: 27513475)
      J Clin Oncol. 2011 Feb 1;29(4):406-12. (PMID: 21172892)
      CA Cancer J Clin. 2017 Jan;67(1):7-30. (PMID: 28055103)
      Breast. 2017 Feb;31:150-156. (PMID: 27866090)
      J Med Internet Res. 2017 Sep 14;19(9):e322. (PMID: 28912116)
    • Publication Date:
      Date Created: 20190711 Date Completed: 20200220 Latest Revision: 20200309
    • Publication Date:
      20240105
    • Accession Number:
      PMC6620008
    • Accession Number:
      10.1371/journal.pone.0219093
    • Accession Number:
      31291302